腹腔镜与开腹远端胃切除术治疗局部进展期胃癌的5年结局:KLASS-02随机临床试验
KLASS-02多中心随机临床试验纳入1050例局部进展期胃癌患者,其中974例接受R0切除,比较腹腔镜与开腹远端胃切除术的5年随访结果。腹腔镜组与开腹组的5年总生存率(88.9% vs 88.7%)和无复发生存率(79.5% vs 81.1%)无显著差异,且腹腔镜组晚期并发症发生率显著更低(6.5% vs 11.0%)。5年结果支持腹腔镜手术相较于开腹手术的非劣效性,推荐用于局部进展期胃癌患者。
要点
- 腹腔镜与开腹远端胃切除术的5年OS和RFS无显著差异,支持非劣效性。
- 腹腔镜组晚期并发症发生率显著低于开腹组(6.5% vs 11.0%)。
- 两组复发类型在各分期均无差异,最常见为腹膜癌病(42.1%)。
核心结论
- KLASS-02试验5年结局支持腹腔镜远端胃切除术治疗局部进展期胃癌不劣于开腹手术。
- 推荐腹腔镜入路用于局部进展期胃癌患者,以获得低晚期并发症发生率的获益。
研究设计与样本
- 多中心随机临床试验(KLASS-02),2011年11月21日至2015年4月29日纳入20至80岁术前诊断为局部进展期胃癌患者。
- 共1050例入组,974例接受R0切除,其中腹腔镜组492例(50.5%),开腹组482例(49.5%)。
- 主要评估5年总生存率、无复发生存率、复发模式和长期手术并发症。
主要发现
- 腹腔镜组与开腹组5年OS分别为88.9%和88.7%,无显著差异。
- 腹腔镜组与开腹组5年RFS分别为79.5%和81.1%,无显著差异。
- 最常见的复发类型为腹膜癌病(73/173,42.1%),其次为血行转移(36/173,20.8%)和局部复发(23/173,13.2%)。
- 各肿瘤分期的复发类型在两组间无差异。
- III期胃癌患者个体水平3年RFS与5年OS相关性最高(ρ=0.720)。
关键数值与推荐
- 腹腔镜组晚期并发症发生率为6.5%(32/492),开腹组为11.0%(53/482),差异显著。
- 两组最常见并发症均为肠梗阻,腹腔镜组13/492(2.6%),开腹组24/482(5.0%)。
临床怎么用
- 对于局部进展期胃癌,腹腔镜远端胃切除术可作为开腹手术的替代选择,长期肿瘤学结局非劣效。
- 腹腔镜入路可能降低晚期并发症发生率,尤其是肠梗阻。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The long-term safety of laparoscopic distal gastrectomy for locally advanced gastric cancer (AGC) remains uncertain given the lack of 5-year follow-up results. OBJECTIVE: To compare the 5-year follow-up results in patients with clinically AGC enrolled in the Korean Laparoendoscopic Gastrointestinal Surgery Study (KLASS)-02 randomized clinical trial who underwent laparoscopic or open distal gastrectomy. DESIGN, SETTING, AND PARTICIPANTS: The KLASS-02, a multicenter randomized clinical trial, showed that laparoscopic surgery was noninferior to open surgery for patients with locally AGC. The present study assessed the 5-year follow-up results, including 5-year overall survival (OS) and relapse-free survival (RFS) rates and long-term complications, in patients enrolled in KLASS-02. From November 21, 2011, to April 29, 2015, patients aged 20 to 80 years diagnosed preoperatively with locally AGC were enrolled. Final follow-up was on June 15, 2021. Data were analyzed June 24 to September 9, 2021. INTERVENTIONS: Patients were treated with R0 resection either by laparoscopic gastrectomy or open gastrectomy as the full analysis set of the KLASS-02 trial. MAIN OUTCOMES AND MEASURES: Five-year OS and RFS rates, recurrence patterns, and long-term surgical complications were evaluated. RESULTS: This study enrolled a total of 1050 patients. A total of 974 patients were treated with R0 resection; 492 (50.5%) in the laparoscopic gastrectomy group (mean [SD] age, 59.8 [11.0] years; 351 men [71.3%]) and 482 (49.5%) in the open gastrectomy group (mean [SD] age, 59.4 [11.5] years; 335 men [69.5%]). In patients who underwent laparoscopic and open distal gastrectomy, the 5-year OS (88.9% vs 88.7%) and RFS (79.5% vs 81.1%) rates did not differ significantly. The most common types of recurrence were peritoneal carcinomatosis (73 of 173 [42.1%]), hematogenous metastases (36 of 173 [20.8%]), and locoregional recurrence (23 of 173 [13.2%]), with no between-group differences in types of recurrence at each cancer stage. The correlation between 3-year RFS and 5-year OS at the individual level was highest in patients with stage III gastric cancer (ρ = 0.720). The late complication rate was significantly lower in the laparoscopic than in the open surgery group (32 of 492 [6.5%] vs 53 of 482 [11.0%]). The most common type of complication in both groups was intestinal obstruction (13 of 492 [2.6%] vs 24 of 482 [5.0%]). CONCLUSIONS AND RELEVANCE: The 5-year outcomes of the KLASS-02 trial support the 3-year results, which is the noninferiority of laparoscopic surgery compared with open gastrectomy for locally AGC. The laparoscopic approach can be recommended in patients with locally AGC to achieve the benefit of low incidence of late complications. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01456598.
引用
- Son SY, Hur H, Hyung WJ, et al. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: 5-Year Outcomes of the KLASS-02 Randomized Clinical Trial. JAMA Surg. 2022. PMID: 35857305. doi:10.1001/jamasurg.2022.2749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。